Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

Mechanisms and insights into drug resistance in cancer

Hiba Zahreddine, Katherine L. B. Borden

Frontiers in Pharmacology · 2013

doi:10.3389/fphar.2013.00028

Abstract

Cancer drug resistance continues to be a major impediment in medical oncology. Clinically, resistance can arise prior to or as a result of cancer therapy. In this review, we discuss different mechanisms adapted by cancerous cells to resist treatment, including alteration in drug transport and metabolism, mutation and amplification of drug targets, as well as genetic rewiring which can lead to impaired apoptosis. Tumor heterogeneity may also contribute to resistance, where small subpopulations of cells may acquire or stochastically already possess some of the features enabling them to emerge under selective drug pressure. Making the problem even more challenging, some of these resistance pathways lead to multidrug resistance, generating an even more difficult clinical problem to overcome. We provide examples of these mechanisms and some insights into how understanding these processes can influence the next generation of cancer therapies.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

CANCER TALE: ITS TREATMENT AND RELAPSE

In 1961, Frei and Freireich initiated the high-dose four-drug combination clinical trial for the treatment of pediatric leukemia. Despite the threat imposed by administering four drugs at once, few weeks following treatment onset, children began to respond, “the bone marrow biopsies came back one after another—all without leukemia cells. Red blood cells and white blood cells and platelets sprouted up in an otherwise scorched field of bone marrow. But the leukemia did not return”. Out of the 16 enrolled patients, 11 showed complete remission. This outstanding success, however, was short-lived. With the exception of a handful of children, all patients eventually relapsed, developing a more vigorous form of cancer that was no longer responsive to the treatment: leukemic cells had invaded the blood–brain barrier and colonized the brain “the only place unreachable by chemotherapy....the children died one after the other-felled by virtue of the adaptation designed to protect them… it was a consequence of the body’s defense system subverting cancer treatment”. To date, this story still reflects the same tale of cancer treatment where its resistance and relapse remains a major challenge. In this review we provide an overview of advances made in our understanding of the mechanisms that enable cancerous cells to adapt to and eventually overcome therapy, and how identifying these mechanisms can help circumvent resistance and improve treatment.

Despite its complex biological nature, many recent successes have been made in the treatment of cancer, including most strikingly chronic myeloid leukemia (CML) and acute promyelocytic leukemia (APL) which have met with great success as well as many cases of pediatric leukemias, Hodgkin’s lymphomas, and testicular cancers. These success stories mainly relied on an increased understanding of the diverse molecular mechanisms governing tumor development. Owing to this, various anti-cancer therapies were designed to target disease-specific mechanisms that are absent in normal cells. Such strategies include (i) inhibition of a specific oncoprotein, such as targeting the oncogenic fusion proteins Bcr–Abl and PML–RARA with Gleevec and all trans retinoic acid (ATRA) with arsenic trioxide respectively or (ii) activation of a specific immune response against cancerous cells demonstrated by the use of interferon alpha alone or in combination with other anti-cancer drugs including 5-fluorouracil and cytarabine. Many of these drugs are currently being used in the clinic and have established positive impact on patient survival. However, a major impediment to their success is the development of therapeutic resistance which in some cases predates clinical intervention. Based on tumor response to the initial therapy, cancer resistance can be broadly classified into two categories, primary and acquired. While primary drug resistance exists prior to any given treatment, acquired resistance occurs after initial therapy. Unfortunately, the majority of patients will likely develop resistance at a certain point of treatment. For example, 50–70% of patients with adenocarcinoma relapse following surgery with a chemoresistant phenotype, and approximately 20% of adults with acute lymphoblastic leukemia suffer from primary resistance to treatment. In addition, primary resistance has been recognized in nearly 50% of all cancer patients in the 1990s. Therefore, the design of anti-cancer drugs that are fully effective necessitates a better understanding of the mechanisms by which cancer cells elude treatment. Here we will discuss several features of drug resistant cells including modification of drug transport, mutation of extracellular receptors, amplification and mutation of drug targets as well as related topics. Additionally, we will briefly address the important question of how resistant cell populations emerge.

MECHANISMS OF DRUG RESISTANCE

Both primary and acquired resistance can be caused by alterations to drug metabolism (sequestrations or enhanced detoxification) or modifications to the drug targets. A brief overview of these mechanisms supported with examples of clinical relevance are presented below (Figure 1).

Perhaps the most studied mode of resistance involves drug metabolism, including its uptake, efflux, and detoxification. The means by which drugs enter cells depend on their chemical nature, and it mainly necessitates the use of receptors, which they bind to and transmit their effects without cellular entry, or transporters, which allow their cellular entry. At this level, resistance can result from mutations that modify activity or reduce the expression of surface receptors and transporters. For instance, mutations or reduced expression of the extracellular receptor smoothened, nucleoside transporters or one or both folate transporters result in defective uptake of cyclopamine, nucleoside drugs, such as cytarabine, and toxic folate analogs, such as methotrexate, respectively. On the other hand, enhanced drug efflux is frequently caused by increased expression of ATP binding cassette (ABC) membrane transporters. Among the 48 known ABC transporters in humans, elevation of three members, P-gp (MDR1 gene product), Multidrug resistance-associated protein 1 (MRP1) and mitoxantrone resistance protein [MXR; also known as breast cancer resistance protein (BCRP) or placenta ABC protein (ABC-P)], have been correlated with cancer chemoresistance to various drugs. For instance, P-gp transports a wide variety of hydrophobic anti-cancer drugs such as vinblastine, doxorubicin, vincristine, and taxol, and therefore its increased expression has been correlated with resistance to these. MRP1 on the other hand, transports negatively charged natural-product drugs in addition to drugs that have been modified by the conjugation of glutathione (GSH), glucuronic acid or sulfate; while, MXR overexpression has been correlated with resistance to topoisomerase I inhibitors, anthracyclines, and mitoxantrone. As can be seen, these factors comprise a major site for the development of drug resistance.

To exert their cytotoxic effects, many anti-cancer drugs must undergo metabolic activation. For instance, cytarabine (also known as AraC), a nucleoside drug widely used for the treatment of acute myelogenous leukemia, necessitates initial phosphorylation by deoxycytidine kinase to cytarabine-monophosphate which is subsequently phosphorylated to the active form cytarabine triphosphate. To circumvent the effects of these drugs, cancer cells develop resistance through decreased drug activation. This occurs via the downregulation or mutation of enzymes involved in this metabolic pathway, such as deoxycytidine kinase in the case of cytarabine. Drug inactivation can also play a major role in the development of resistance. These mechanisms include, for example, conjugation of the drug to GSH, a powerful anti-oxidant that protects the cells against the damaging effects of reactive oxygen species. GSH conjugation to platinum drugs, such as oxaliplatin and cisplatin used in the treatment of various types of cancers, renders them substrates for ABC transporters which enhances drug efflux. Furthermore, the topoisomerase I inhibitor, irinotecan, used for treating colon cancer, have been shown to become inactivated via phase I drug metabolizing enzymes, CYP450. Finally, binding of platinum drugs, particularly cisplatin, to metallothionein (MT), a small cysteine-rich protein, is another means of drug inactivation.

Many cancer cells develop an overreliance or dependency on an oncogene. This is referred to as oncogene addiction. Targeting such oncogenes, provided a basis for the development of targeted therapies. Examples of such targeted therapies include: (i) imatinib targeting BCR/ABL tyrosine kinase in CML, (ii) gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) tyrosine kinase domain in non-small cell lung carcinoma, and (iii) trastuzumab targeting human epidermal growth factor receptor-2 (HER-2) receptor in breast carcinomas. Unfortunately, the long term effectiveness of these drugs is hindered by the development of drug resistance due to mutation of the targeted protein. In the case of BCR/ABL and EGFR inhibitors, resistance emerges as a result of mutations occurring at the gatekeeper residues of the kinase domain which disables drug binding. Furthermore, it has been demonstrated that resistance mutations can be detected prior to treatment in small subpopulations of tumor cells suggesting that these mutant forms were selected via the targeted therapy used. In essence, understanding how mutations in the target proteins confer resistance enables the development of new therapeutic approaches to surmount resistance. For instance, second generation CML inhibitors have been developed based on mutational studies of patients who have become Gleevec resistant.

Other mechanisms by which cancerous cells circumvent the effects of targeted inhibitors have also been described, including amplification of alternative oncogenes or inactivation of alternative survival pathways. In some cases, targeting of one protein alone (that cells are showing dependency on) can become ineffective because another parallel pathway supports tumor survival. In this case, the two pathways develop a synthetic lethal relationship. This way, the loss/inactivation of one of these genes would be supported by the other pathway and for the most effective treatment, one would need to target both pathways.

An example of new pathways emerging once another pathway is targeted comes from the work of, showed that acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors (such as ZSTK474) was due to the upregulation of insulin-like growth factor 1 receptor (IGF1R) pathway and that inhibition of this pathway with selective IGF1R inhibitors reverses the acquired PI3Ki resistance phenotype. Additionally, resistance could result from evasion of apoptotic pathways triggered by the acquisition of either inactivating mutations in genes coding for apoptotic proteins, such as p53, or activating mutations in genes coding for anti-apoptotic proteins, such as B cell lymphoma 2 (Bcl-2; ). Indeed p53 mutations have been correlated with de novo resistance to doxorubicin treatment in patients with advanced breast cancer, as well as resistance to anthracyclines in a mouse sarcoma tumor model.

Another excellent example of this phenomenon (i.e., synthetic lethality) is seen in breast and ovarian cancers carrying mutations in the BRCA1 and BRCA2 genes, important mediators of DNA double-strand break (DSB) repair. When the poly (ADP-ribose) polymerase (PARP) protein, which is involved in different cellular processes including DNA repair, was targeted in these tumors, selective cancer cell toxicity was achieved. Several PARP inhibitors (PARPi) are currently being tested in clinical trials, such as iniparib (phase III ongoing; ) and veliparib cancer, among others. However, despite the promising results these inhibitors showed, whether used as a mono- or combinatorial therapy, cancer cells once again were capable of evolving resistance to PARPi in preclinical and clinical settings. The mechanisms of resistance to these inhibitors have been grouped in to at least four categories, as summarized recently. But perhaps the most distinct of these, was the ability of cancer cells to revert sensitivity to PARPi by acquiring deletion of the mutation in BRCA gene, thus restoring its function and the subsequent repair of DSBs.

DEVELOPMENT OF CROSS RESISTANCE

An important feature of drug resistance, is that development of resistance to one drug can lead to resistance to other drugs. For instance, loss of a drug transporter can lead to resistance to structurally diverse compounds that utilize it or elevation of ABC transporters resulting from one therapy will influence the efficacy of many other compounds. Since this multidrug resistance phenotype correlates with poor chemotherapy response, drug development strategies to overcome this problem are being designed. These include drugs that are not recognized by transporters and therefore evade efflux, efflux inhibitors, drugs that are selectively lethal to P-gp expressing cells, etc.. But, perhaps resistance is not useless after all, as proposed. The alternative strategy to treat the progeny of the drug imposed Darwinian selection process is to identify their new “Achilles’ heel,” where resistance to the first given drug conferred a hypersensitivity to an alternate cytotoxic agent to which parental cells were not sensitive to. A phenomenon referred to as “collateral sensitivity”, which could be considered as a type of synthetic lethality as well since the same genetic alteration that rendered the cells resistant to one drug now sensitizes them to another.

WHERE DO RESISTANT CELLS COME FROM?

The development of human cancers is a complex multistage process involving accumulation of both genetic and epigenetic alterations over time. As a consequence, a single tumor is comprised of heterogeneous populations of cells with distinct genetic fingerprints. As the tumor progresses, some cells undergo genetic alterations, with selection of those having a superior growth advantage in a given context. An excellent example of tumor heterogeneity is provided by breast cancer studies. demonstrated that about 97% of epithelial breast carcinomas possess high levels of intra-tumor diverseness. The relevance of this innate heterogeneity is seen in cancer resistance. Since cancer cell selection obeys the Darwinian law of evolution, hence, under therapeutic pressure, those populations that are most adaptive or resistant to treatment will be selected for. These clones will then dominate and populate the tumor rendering it highly resistant to the given therapy. The selection process can be rationalized by, at least, two mechanisms. First, the emergence of a dominant cellular population after drug selection since it possesses some favorable characteristics such as a mutated drug binding site. The second mechanism involves the acquisition of stochastic alterations within the cancer cells which provide a survival advantage. The advantage itself, e.g., a mutation in a drug binding site or alteration in drug transporters (as just two examples) could be the same for either of these mechanisms. What is different is the underlying process to generate these biochemical differences.

Two known models, the cancer stem cell (CSC) model, and the environment-mediated drug resistance (EMDR) model, which are not mutually exclusive, could explain the origin of resistant cells. In the CSC model, rare populations of cancer stem cells possess tumor-initiating properties. It is thought that CSCs diverge from normal tissue stem cells or from more-differentiated progenitor cells through dysregulation of self-renewal pathways. Beside modulation of molecular mechanisms, such as increased efficiency of DNA repair, changes in cell cycle parameters, overexpression of anti-apoptotic proteins or drug transporters, etc., resistance of CSCs could be due to their quiescent nature. Thus, in this case, the cell population is present and is difficult to target using traditional chemotherapy strategies many of which depend on active cell cycling.

In the EMDR model, resistance emerges as the cancer cells use their interactions with the surrounding microenvironment to enter into a quiescent or dormant state as a means of circumventing the effects of the given therapy. Under the drug imposed selection pressure, these cells remain in their protective shelter, undergoing genetic changes until they ultimately reach a more permanent acquired resistance phenotype and in turn, alter their surrounding microenvironment. These surviving populations, which may or may not be CSCs, can contribute to minimal residual disease (MRD) and cancer relapse. The EMDR model is relevant to both hematopoietic and metastatic epithelial malignancies. EMDR could be mediated by either soluble or cell adhesion-related microenvironmental factors. Soluble factor-mediated drug resistance occurs through induction of gene transcription within the tumor cells by cytokines, chemokines, or growth factors secreted by neighboring stroma-like fibroblasts. One of the known mediators of this resistance mechanism is interleukin-6 (IL-6), whose increased secretion has been correlated with resistance to various cytotoxins both in in vitro and in vivo models. This includes, for instance, resistance to bortezomib in multiple myeloma and to etoposide and cisplatin in hormone-independent prostate carcinomas. Further, cell adhesion-mediated drug resistance is triggered by the adhesion of integrins from tumor cells to stromal fibroblasts or to components of the surrounding extracellular matrix. Molecularly, this process could be due to many scenarios including (i) degradation of apoptotic proteins or (ii) enhanced stability or altered subcellular distribution of anti-apoptotic proteins and cell cycle regulators. One example is provided by studies into melphalan resistance. In this case, the cancerous cells tend to use their adhesion to fibronectin in the surrounding microenvironment to reduce the endogenous levels of the proapoptotic BH3-only Bcl-2 family member, Bim1, thus conferring resistance by disabling apoptosis. From a clinical point of view, it is thought that combining current therapies with inhibitors of EMDR pathways could enhance the effectiveness of the treatment. A proof-of-principle example was demonstrated by the combination of melphalan, a DNA alkylating agent used in the treatment of multiple myeloma and ovarian carcinomas, with an anti-integrin α-4 antibody (natalizumab) which significantly inhibited myeloma growth and reduced tumor burden in patients.

CONCLUSION

Resistance to drugs continues to be a major problem in oncology affecting the majority of cancer patients. Here we provide many examples of how cells become resistant to various drugs including alteration in drug metabolism, modification of drug targets, and genetic rewiring of cells to bypass targeted pathways. A better understanding of oncogene networks and oncogene cooperativity will likely improve therapeutic strategies by identifying optimal combinations based on the genetic lesions in the tumors. Importantly, tumors are highly heterogenous and this heterogeneity may well substantially contribute to primary or acquired resistance. Armed with a greater understanding of the mechanisms of drug resistance will undoubtedly lead to more long term remissions and hopefully cures.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 149

  1. 1.

    Aas T. Borresen A. L. Geisler S. Smith-Sorensen B. Johnsen H. Varhaug J. E. (1996 ). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 2 811–814

    Not in our library10.1038/nm0796-811

  2. 2.

    Apperley J. F. (2007 ). Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8 1018–1029

    Not in our library10.1016/s1470-2045(07)70342-x

  3. 3.

    Arber N. Doki Y. Han E. K. Sgambato A. Zhou P. Kim N. H.. (1997 ). Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res. 57 1569–1574

    Not in our library

  4. 4.

    Atwood S. X. Chang A. L. Oro A. E. (2012 ). Hedgehog pathway inhibition and the race against tumor evolution. J. Cell Biol. 199 193–197

    Not in our library10.1083/jcb.201207140

  5. 5.

    Balak M. N. Gong Y. Riely G. J. Somwar R. Li A. R. Zakowski M. F. (2006 ). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12 6494–6501

    Not in our library10.1158/1078-0432.ccr-06-1570

  6. 6.

    Bardenheuer W. Lehmberg K. Rattmann I. Brueckner A. Schneider A. Sorg U. R. (2005 ). Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 19 2281–2288

    Not in our library10.1038/sj.leu.2403977

  7. 7.

    Bean J. Riely G. J. Balak M. Marks J. L. Ladanyi M. Miller V. A. (2008 ). Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin. Cancer Res. 14 7519–7525

    Not in our library10.1158/1078-0432.ccr-08-0151

  8. 8.

    Bidard F. C. Vincent-Salomon A. Gomme S. Nos C. De Rycke Y. Thiery J. P. (2008 ). Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin. Cancer Res. 14 3306–3311

    Not in our library10.1158/1078-0432.ccr-07-4749

  9. 9.

    Blencke S. Ullrich A. Daub H. (2003 ). Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 278 15435–15440

    Not in our library10.1074/jbc.m211158200

  10. 10.

    Borsellino N. Belldegrun A. Bonavida B. (1995 ). Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 55 4633–4639

    Not in our library

  11. 11.

    Borsellino N. Bonavida B. Ciliberto G. Toniatti C. Travali S D’Alessandro N. (1999 ). Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer 85 134–144

    Not in our library

  12. 12.

    Borst P. Evers R. Kool M. Wijnholds J. (2000 ). A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 1295–1302

    Not in our library10.1093/jnci/92.16.1295

  13. 13.

    Braun S. Kentenich C. Janni W. Hepp F. De Waal J. Willgeroth F. (2000 ). Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J. Clin. Oncol. 18 80–86

    Not in our library10.1200/jco.2000.18.1.80

  14. 14.

    Breivik J. (2005 ). The evolutionary origin of genetic instability in cancer development. Semin. Cancer Biol. 15 51–60

    Not in our library10.1016/j.semcancer.2004.09.008

  15. 15.

    Bryant H. E. Schultz N. Thomas H. D. Parker K. M. Flower D. Lopez E. (2005 ). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 913–917

    Not in our library10.1038/nature03443

  16. 16.

    Cai J. Weiss M. L. Rao M. S. (2004 ). In search of “stemness”. Exp. Hematol. 32 585–598

    Not in our library10.1016/j.exphem.2004.03.013

  17. 17.

    Campbell P. J. Stephens P. J. Pleasance E. D. O’Meara S. Li H. Santarius T. (2008 ). Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 40 722–729

    Not in our library10.1038/ng.128

  18. 18.
    Implication of Tumor Microenvironment in Chemoresistance: Tumor-Associated Stromal Cells Protect Tumor Cells from Cell Death · 2012
    No notice
  19. 19.

    Caulin A. F. Maley C. C. (2011 ). Peto’s Paradox: evolution’s prescription for cancer prevention. Trends Ecol. Evol. 26 175–182

    Not in our library10.1016/j.tree.2011.01.002

  20. 20.

    Chiarugi A. (2012 ). A snapshot of chemoresistance to PARP inhibitors. Trends Pharmacol. Sci. 33 42–48

    Not in our library10.1016/j.tips.2011.10.001

  21. 21.

    Chin L. Gray J. W. (2008 ). Translating insights from the cancer genome into clinical practice. Nature 452 553–563

    Not in our library10.1038/nature06914

  22. 22.
    BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations · 2007
    No notice
  23. 23.

    Crespi B. Summers K. (2005 ). Evolutionary biology of cancer. Trends Ecol. Evol. 20 545–552

    Not in our library10.1016/j.tree.2005.07.007

  24. 24.

    Croix B. S. Rak J. W. Kapitain S. Sheehan C. Graham C. H. Kerbel R. S. (1996 ). Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J. Natl. Cancer Inst. 88 1285–1296

    Not in our library10.1093/jnci/88.18.1285

  25. 25.

    Damaraju V. L. Damaraju S. Young J. D. Baldwin S. A. Mackey J. Sawyer M. B. (2003 ). Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene 22 7524–7536

    Not in our library10.1038/sj.onc.1206952

  26. 26.

    Druker B. J. Talpaz M. Resta D. J. Peng B. Buchdunger E. Ford J. M. (2001 ). Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344 1031–1037

    Not in our library10.1056/nejm200104053441401

  27. 27.

    Engelhardt B. Kappos L. (2008 ). Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener. Dis. 5 16–22

    Not in our library10.1159/000109933

  28. 28.

    Engelman J. A. Zejnullahu K. Mitsudomi T. Song Y. Hyland C. Park J. O. (2007 ). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 1039–1043

    Not in our library10.1126/science.1141478

  29. 29.

    Farmer H. Mccabe N. Lord C. J. Tutt A. N. Johnson D. A. Richardson T. B. (2005 ). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 917–921

    Not in our library10.1038/nature03445

  30. 30.

    Ferrantini M. Capone I. Belardelli F. (2007 ). Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89 884–893

    Not in our library10.1016/j.biochi.2007.04.006

  31. 31.

    Frassanito M. A. Cusmai A. Iodice G. Dammacco F. (2001 ). Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97 483–489

    Not in our library10.1182/blood.v97.2.483

  32. 32.

    Frei E. III, Karon M. Levin R. H. Freireich E. J. Taylor R. J. Hananian J. (1965 ). The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. Blood 26 642–656

    Not in our library

  33. 33.

    Galmarini C. M. Mackey J. R. Dumontet C. (2001 ). Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15 875–890

    Not in our library10.1038/sj.leu.2402114

  34. 34.

    Gatti L. Zunino F. (2005 ). Overview of tumor cell chemoresistance mechanisms. Methods Mol. Med. 111 127–148

    Not in our library10.1385/1-59259-889-7:127

  35. 35.

    Gioeli D. (2011 ). Targeted Therapies Mechanisms of Resistance. New York: Humana Press

    Not in our library

  36. 36.

    Giona F. Testi A. M. Annino L. Amadori S. Arcese W. Camera A. (1994 ). Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Associazione Italiana Ematologia ed Ocologia Pediatrica. Br. J. Haematol. 86 55–61

    Not in our library10.1111/j.1365-2141.1994.tb03252.x

  37. 37.

    Goldman J. M. Melo J. V. (2003 ). Chronic myeloid leukemia – advances in biology and new approaches to treatment. N. Engl. J. Med. 349 1451–1464

    Not in our library10.1056/nejmra020777

  38. 38.

    Gorre M. E. Mohammed M. Ellwood K. Hsu N. Paquette R. Rao P. N. (2001 ). Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science 293 876–880

    Not in our library10.1126/science.1062538

  39. 39.

    Gottesman M. M. (2002 ). Mechanisms of cancer drug resistance. Annu. Rev. Med. 53 615–627

    Not in our library10.1146/annurev.med.53.082901.103929

  40. 40.

    Gottesman M. M. Fojo T. Bates S. E. (2002 ). Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2 48–58

    Not in our library10.1038/nrc706

  41. 41.

    Greaves M. (2007 ). Darwinian medicine: a case for cancer. Nat. Rev. Cancer 7 213–221

    Not in our library10.1038/nrc2071

  42. 42.

    Guha M. (2011 ). PARP inhibitors stumble in breast cancer. Nat. Biotechnol. 29 373–374

    Not in our library10.1038/nbt0511-373

  43. 43.

    Guilhot F. Chastang C. Michallet M. Guerci A. Harousseau J. L. Maloisel F. (1997 ). Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N. Engl. J. Med. 337 223–229

    Not in our library10.1056/nejm199707243370402

  44. 44.

    Hall M. D. Handley M. D. Gottesman M. M. (2009 ). Is resistance useless? Multidrug resistance and collateral sensitivity. Trends Pharmacol. Sci. 30 546–556

    Not in our library10.1016/j.tips.2009.07.003

  45. 45.

    Hanahan D. Weinberg R. A. (2011 ). Hallmarks of cancer: the next generation. Cell 144 646–674

    Not in our library10.1016/j.cell.2011.02.013

  46. 46.

    Hartman J. L. T. Garvik B. Hartwell L. (2001 ). Principles for the buffering of genetic variation. Science 291 1001–1004

    Not in our library10.1126/science.1056072

  47. 47.

    Hazlehurst L. A. Argilagos R. F. Dalton W. S. (2007 ). Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells. Br. J. Haematol. 136 269–275

    Not in our library10.1111/j.1365-2141.2006.06435.x

  48. 48.

    Hazlehurst L. A. Damiano J. S. Buyuksal I. Pledger W. J. Dalton W. S. (2000 ). Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 19 4319–4327

    Not in our library10.1038/sj.onc.1203782

  49. 49.

    Hazlehurst L. A. Enkemann S. A. Beam C. A. Argilagos R. F. Painter J. Shain K. H. (2003 ). Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 63 7900–7906

    Not in our library

  50. 50.

    Hazlehurst L. A. Valkov N. Wisner L. Storey J. A. Boulware D. Sullivan D. M. (2001 ). Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98 1897–1903

    Not in our library10.1182/blood.v98.6.1897

  51. 51.

    Heppner G. H. Dexter D. L. Denucci T. Miller F. R. Calabresi P. (1978 ). Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res. 38 3758–3763

    Not in our library

  52. 52.

    Hipfner D. R. Deeley R. G. Cole S. P. (1999 ). Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta 1461 359–376

    Not in our library10.1016/s0005-2736(99)00168-6

  53. 53.

    Hofmann W. K. Komor M. Wassmann B. Jones L. C. Gschaidmeier H. Hoelzer D. (2003 ). Presence of the BCR–ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood 102 659–661

    Not in our library10.1182/blood-2002-06-1756

  54. 54.

    Hughes T. P. Kaeda J. Branford S. Rudzki Z. Hochhaus A. Hensley M. L. (2003 ). Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 349 1423–1432

    Not in our library10.1056/nejmoa030513

  55. 55.

    Inukai M. Toyooka S. Ito S. Asano H. Ichihara S. Soh J. (2006 ). Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66 7854–7858

    Not in our library10.1158/0008-5472.can-06-1951

  56. 56.

    Ishikawa T. Ali-Osman F. (1993 ). Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem. 268 20116–20125

    Not in our library

  57. 57.

    Isoyama S. Dan S. Nishimura Y. Nakamura N. Kajiwara G. Seki M. (2012 ). Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance. Cancer Sci. 103 1955–1960

    Not in our library10.1111/cas.12004

  58. 58.

    Jabbour E. Kantarjian H. Jones D. Breeden M. Garcia-Manero G. O’Brien S. (2008 ). Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 112 53–55

    Not in our library10.1182/blood-2007-11-123950

  59. 59.

    Jabbour E. Kantarjian H. Jones D. Talpaz M. Bekele N. O’Brien S. (2006 ). Frequency and clinical significance of BCR–ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20 1767–1773

    Not in our library10.1038/sj.leu.2404318

  60. 60.

    Jedlitschky G. Leier I. Buchholz U. Barnouin K. Kurz G. Keppler D. (1996 ). Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 56 988–994

    Not in our library

  61. 61.

    Juvekar A. Burga L. N. Hu H. Lunsford E. P. Ibrahim Y. H. Balmana J. (2012 ). Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2 1048–1063

    Not in our library10.1158/2159-8290.cd-11-0336

  62. 62.

    Kasahara K. Fujiwara Y. Nishio K. Ohmori T. Sugimoto Y. Komiya K. (1991 ). Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res. 51 3237–3242

    Not in our library

  63. 63.

    Kasper M. Toftgard R. (2013 ). Smoothing out drug resistance. Cancer Cell 23 3–5

    Not in our library10.1016/j.ccr.2012.12.011

  64. 64.

    Kelley S. L. Basu A. Teicher B. A. Hacker M. P. Hamer D. H. Lazo J. S. (1988 ). Overexpression of metallothionein confers resistance to anticancer drugs. Science 241 1813–1815

    Not in our library10.1126/science.3175622

  65. 65.

    Kelly R. J. Draper D. Chen C. C. Robey R. W. Figg W. D. Piekarz R. L. (2011 ). A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin. Cancer Res. 17 569–580

    Not in our library10.1158/1078-0432.ccr-10-1725

  66. 66.

    Kobayashi S. Boggon T. J. Dayaram T. Janne P. A. Kocher O. Meyerson M. (2005 ). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 786–792

    Not in our library10.1056/nejmoa044238

  67. 67.

    Konig J. Nies A. T. Cui Y. Leier I. Keppler D. (1999 ). Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta 1461 377–394

    Not in our library10.1016/s0005-2736(99)00169-8

  68. 68.

    Kreitman R. J. (2006 ). Immunotoxins for targeted cancer therapy. AAPS J. 8 E532–E551

    Not in our library10.1208/aapsj080363

  69. 69.

    Kreitman R. J. Wilson W. H. Bergeron K. Raggio M. Stetler-Stevenson M. Fitzgerald D. J. (2001 ). Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345 241–247

    Not in our library10.1056/nejm200107263450402

  70. 70.

    Krishnamurthy P. Ross D. D. Nakanishi T. Bailey-Dell K. Zhou S. Mercer K. E. (2004 ). The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 279 24218–24225

    Not in our library10.1074/jbc.m313599200

  71. 71.

    Kufe D. W. Spriggs D. R. (1985 ). Biochemical and cellular pharmacology of cytosine arabinoside. Semin. Oncol. 12 34–48

    Not in our library

  72. 72.

    Kummar S. Chen A. Ji J. Zhang Y. Reid J. M. Ames M. (2011 ). Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res. 71 5626–5634

    Not in our library10.1158/0008-5472.can-11-1227

  73. 73.

    Kummar S. Chen A. Parchment R. E. Kinders R. J. Ji J. Tomaszewski J. E. (2012 ). Advances in using PARP inhibitors to treat cancer. BMC Med. 10:25

    Not in our library10.1186/1741-7015-10-25

  74. 74.

    le Coutre P. Tassi E. Varella-Garcia M. Barni R. Mologni L. Cabrita G. (2000 ). Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95 1758–1766

    Not in our library

  75. 75.

    Levine A. J. (1997 ). p53, the cellular gatekeeper for growth and division. Cell 88 323–331

    Not in our library10.1016/s0092-8674(00)81871-1

  76. 76.
    On evolutionary origin of cancer · 2005
    Not checked
  77. 77.

    Lippert T. H. Ruoff H. J. Volm M. (2011 ). Current status of methods to assess cancer drug resistance. Int. J. Med. Sci. 8 245–253

    Not in our library10.7150/ijms.8.245

  78. 78.

    Longo-Sorbello G. S. Bertino J. R. (2001 ). Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica 86 121–127

    Not in our library

  79. 79.

    Luo J. Solimini N. L. Elledge S. J. (2009 ). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136 823–837

    Not in our library10.1016/j.cell.2009.02.024

  80. 80.

    Lwin T. Hazlehurst L. A. Dessureault S. Lai R. Bai W. Sotomayor E. (2007 ). Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas. Blood 110 1631–1638

    Not in our library10.1182/blood-2006-11-060350

  81. 81.

    Lynch T. J. Bell D. W. Sordella R. Gurubhagavatula S. Okimoto R. A. Brannigan B. W. (2004 ). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 2129–2139

    Not in our library10.1056/nejmoa040938

  82. 82.

    Marusyk A. Polyak K. (2010 ). Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta 1805 105–117

    Not in our library10.1016/j.bbcan.2009.11.002

  83. 83.

    Matsunaga T. Takemoto N. Sato T. Takimoto R. Tanaka I. Fujimi A. (2003 ). Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 9 1158–1165

    Not in our library10.1038/nm909

  84. 84.

    Meads M. B. Gatenby R. A. Dalton W. S. (2009 ). Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9 665–674

    Not in our library10.1038/nrc2714

  85. 85.

    Meijer C. Mulder N. H. Timmer-Bosscha H. Sluiter W. J. Meersma G. J De Vries E. G. (1992 ). Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 52 6885–6889

    Not in our library

  86. 86.

    Michor F. Polyak K. (2010 ). The origins and implications of intratumor heterogeneity. Cancer Prev. Res. (Phila) 3 1361–1364

    Not in our library10.1158/1940-6207.capr-10-0234

  87. 87.

    Monceviciute-Eringiene E. (2005 ). Neoplastic growth: the consequence of evolutionary malignant resistance to chronic damage for survival of cells (review of a new theory of the origin of cancer). Med. Hypotheses 65 595–604

    Not in our library10.1016/j.mehy.2005.02.033

  88. 88.

    Montoni A. Robu M. Pouliot E. Shah G. M. (2013 ). Resistance to PARP-inhibitors in Cancer Therapy. Front. Pharmacol. 4:18

    Not in our library10.3389/fphar.2013.00018

  89. 89.

    Mori Y. Shimizu N. Dallas M. Niewolna M. Story B. Williams P. J. (2004 ). Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104 2149–2154

    Not in our library10.1182/blood-2004-01-0236

  90. 90.

    Mukherjee S. (2010 ). The Emperor of All Maladies: a Biography of Cancer. New York: Scribner

    Not in our library

  91. 91.

    Negrini S. Gorgoulis V. G. Halazonetis T. D. (2010 ). Genomic instability – an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11 220–228

    Not in our library10.1038/nrm2858

  92. 92.

    Nesse R. M. (2001 ). How is Darwinian medicine useful? West. J. Med. 174 358–360

    Not in our library10.1136/ewjm.174.5.358

  93. 93.

    Nguyen L. V. Vanner R. Dirks P. Eaves C. J. (2012 ). Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12 133–143

    Not in our library10.1038/nrc3184

  94. 94.

    Nicolini F. E. Corm S. Le Q. H. Sorel N. Hayette S. Bories D. (2006 ). Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia 20 1061–1066

    Not in our library10.1038/sj.leu.2404236

  95. 95.

    Nijman S. M. (2011 ). Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. 585 1–6

    Not in our library10.1016/j.febslet.2010.11.024

  96. 96.

    Nobili S. Landini I. Mazzei T. Mini E. (2012 ). Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med. Res. Rev. 32 1220–1262

    Not in our library10.1002/med.20239

  97. 97.

    O’Brien C. A. Pollett A. Gallinger S. Dick J. E. (2007 ). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445 106–110

    Not in our library10.1038/nature05372

  98. 98.

    O’Brien S. G. Guilhot F. Larson R. A. Gathmann I. Baccarani M. Cervantes F. (2003 ). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348 994–1004

    Not in our library10.1056/nejmoa022457

  99. 99.

    O’Connor D. Sibson K. Caswell M. Connor P. Cummins M. Mitchell C. (2011 ). Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 154 482–485

    Not in our library10.1111/j.1365-2141.2011.08752.x

  100. 100.

    Palma J. P. Rodriguez L. E. Bontcheva-Diaz V. D. Bouska J. J. Bukofzer G. Colon-Lopez M. (2008 ). The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo. Anticancer. Res. 28 2625–2635

    Not in our library

  101. 101.

    Palma J. P. Wang Y. C. Rodriguez L. E. Montgomery D. Ellis P. A. Bukofzer G. (2009 ). ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin. Cancer Res. 15 7277–7290

    Not in our library10.1158/1078-0432.ccr-09-1245

  102. 102.
    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain · 2005
    No notice
  103. 103.

    Park Y. Gerson S. L. (2005 ). DNA repair defects in stem cell function and aging. Annu. Rev. Med. 56 495–508

    Not in our library10.1146/annurev.med.56.082103.104546

  104. 104.

    Piccart-Gebhart M. J. Procter M. Leyland-Jones B. Goldhirsch A. Untch M. Smith I. (2005 ). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353 1659–1672

    Not in our library10.1056/nejmoa052306

  105. 105.

    Pinedo H. M. Giaccone G. (1998 ). Drug Resistance in the Treatment of Cancer. Cambridge: Cambridge University Press

    Not in our library

  106. 106.

    Pluchino K. M. Hall M. D. Goldsborough A. S. Callaghan R. Gottesman M. M. (2012 ). Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist. Updat. 15 98–105

    Not in our library10.1016/j.drup.2012.03.002

  107. 107.

    Potten C. S. Owen G. Booth D. (2002 ). Intestinal stem cells protect their genome by selective segregation of template DNA strands. J. Cell Sci. 115 2381–2388

    Not in our library10.1242/jcs.115.11.2381

  108. 108.

    Raderer M. Scheithauer W. (1995 ). Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-alpha: an overview of clinical trials. Eur. J. Cancer 31A 1002–1008

    Not in our library10.1016/0959-8049(95)00078-x

  109. 109.

    Ricci-Vitiani L. Lombardi D. G. Pilozzi E. Biffoni M. Todaro M. Peschle C. (2007 ). Identification and expansion of human colon-cancer-initiating cells. Nature 445 111–115

    Not in our library10.1038/nature05384

  110. 110.

    Riffell J. L. Lord C. J. Ashworth A. (2012 ). Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat. Rev. Drug Discov. 11 923–936

    Not in our library10.1038/nrd3868

  111. 111.

    Sampath D. Cortes J. Estrov Z. Du M. Shi Z. Andreeff M. (2006 ). Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107 2517–2524

    Not in our library10.1182/blood-2005-08-3351

  112. 112.

    Sawyers C. (2004 ). Targeted cancer therapy. Nature 432 294–297

    Not in our library10.1038/nature03095

  113. 113.

    Schvimer M. Lash R. H. Katzin W. E. (1995 ). Intratumoral heterogeneity of DNA ploidy in breast carcinomas: a flow cytometric assessment of sampling techniques. Cytometry 22 292–296

    Not in our library10.1002/cyto.990220405

  114. 114.

    Sellers W. R. (2011 ). A blueprint for advancing genetics-based cancer therapy. Cell 147 26–31

    Not in our library10.1016/j.cell.2011.09.016

  115. 115.

    Shain K. H. Landowski T. H. Dalton W. S. (2002 ). Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 168 2544–2553

    Not in our library10.4049/jimmunol.168.5.2544

  116. 116.

    Shain K. H. Yarde D. N. Meads M. B. Huang M. Jove R. Hazlehurst L. A. (2009 ). Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 69 1009–1015

    Not in our library10.1158/0008-5472.can-08-2419

  117. 117.

    Sharma S. V. Settleman J. (2007 ). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21 3214–3231

    Not in our library10.1101/gad.1609907

  118. 118.

    Shen C. Y. Yu J. C. Lo Y. L. Kuo C. H. Yue C. T. Jou Y. S. (2000 ). Genome-wide search for loss of heterozygosity using laser capture microdissected tissue of breast carcinoma: an implication for mutator phenotype and breast cancer pathogenesis. Cancer Res. 60 3884–3892

    Not in our library

  119. 119.

    Shen Z. (2011 ). Genomic instability and cancer: an introduction. J. Mol. Cell Biol. 3 1–3

    Not in our library10.1093/jmcb/mjq057

  120. 120.

    Shepherd F. A. Rodrigues Pereira J. Ciuleanu T. Tan E. H. Hirsh V. Thongprasert S. (2005 ). Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353 123–132

    Not in our library10.1056/nejmoa050753

  121. 121.

    Siegel R. Desantis C. Virgo K. Stein K. Mariotto A. Smith T. (2012 ). Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62 220–241

    Not in our library10.3322/caac.21149

  122. 122.

    Slamon D. J. Leyland-Jones B. Shak S. Fuchs H. Paton V. Bajamonde A. (2001 ). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344 783–792

    Not in our library10.1056/nejm200103153441101

  123. 123.

    Soverini S. Martinelli G. Rosti G. Bassi S. Amabile M. Poerio A. (2005 ). ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J. Clin. Oncol. 23 4100–4109

    Not in our library10.1200/jco.2005.05.531

  124. 124.

    Stratton M. R. Campbell P. J. Futreal P. A. (2009 ). The cancer genome. Nature 458 719–724

    Not in our library10.1038/nature07943

  125. 125.

    Tallman M. S. Nabhan C. Feusner J. H. Rowe J. M. (2002 ). Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 99 759–767

    Not in our library10.1182/blood.v99.3.759

  126. 126.

    Taron M. Ichinose Y. Rosell R. Mok T. Massuti B. Zamora L. (2005 ). Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. 11 5878–5885

    Not in our library10.1158/1078-0432.ccr-04-2618

  127. 127.

    Teicher B. A. (2006 ). Cancer Drug Resistance. Totowa: Humana Press

    Not in our library

  128. 128.

    Testi A. M. Moleti M. L. Giona F. Iori A. P. Meloni G. Miniero R. (1992 ). Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children. Ann. Oncol. 3 765–767

    Not in our library10.1093/oxfordjournals.annonc.a058336

  129. 129.

    The International Cancer Genome Consortium. (2010 ). International network of cancer genome projects. Nature 464 993–998

    Not in our library10.1038/nature08987

  130. 130.

    Thomas D. A. Kantarjian H. Smith T. L. Koller C. Cortes J. O’Brien S. (1999 ). Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86 1216–1230

    Not in our library10.1002/(sici)1097-0142(19991001)86:7<1216::aid-cncr17>3.0.co;2-o

  131. 131.

    Toyooka S. Kiura K. Mitsudomi T. (2005 ). EGFR mutation and response of lung cancer to gefitinib. N. Engl. J. Med. 352, 2136; author reply 2136

    Not in our library10.1056/nejm200505193522019

  132. 132.

    Trudeau M. E. Crump M. Charpentier D. Yelle L. Bordeleau L. Matthews S. (2006 ). Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada – Clinical Trials Group (NCIC-CTG). Ann. Oncol. 17 952–956

    Not in our library10.1093/annonc/mdl056

  133. 133.

    Tucker C. L. Fields S. (2003 ). Lethal combinations. Nat. Genet. 35 204–205

    Not in our library10.1038/ng1103-204

  134. 134.

    Ullah M. F. (2008 ). Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac. J. Cancer Prev. 9 1–6

    Not in our library

  135. 135.
    Molecular Signatures of Proliferation and Quiescence in Hematopoietic Stem Cells · 2004
    No notice
  136. 136.

    Voorhees P. M. Chen Q. Kuhn D. J. Small G. W. Hunsucker S. A. Strader J. S. (2007 ). Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin. Cancer Res. 13 6469–6478

    Not in our library10.1158/1078-0432.ccr-07-1293

  137. 137.

    Wang S. Yang D. Lippman M. E. (2003 ). Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin. Oncol. 30 133–142

    Not in our library10.1053/j.seminoncol.2003.08.015

  138. 138.

    Weaver V. M. Petersen O. W. Wang F. Larabell C. A. Briand P. Damsky C. (1997 ). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137 231–245

    Not in our library10.1083/jcb.137.1.231

  139. 139.

    Weinstein I. B. (2002 ). Cancer. Addiction to oncogenes – the Achilles heal of cancer. Science 297 63–64

    Not in our library10.1126/science.1073096

  140. 140.

    Weinstein I. B. Joe A. K. (2006 ). Mechanisms of disease: oncogene addiction – a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 3 448–457

    Not in our library10.1038/ncponc0558

  141. 141.

    White D. E. Kurpios N. A. Zuo D. Hassell J. A. Blaess S. Mueller U. (2004 ). Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6 159–170

    Not in our library10.1016/j.ccr.2004.06.025

  142. 142.

    Wild P. Knuechel R. Dietmaier W. Hofstaedter F. Hartmann A. (2000 ). Laser microdissection and microsatellite analyses of breast cancer reveal a high degree of tumor heterogeneity. Pathobiology 68 180–190

    Not in our library10.1159/000055921

  143. 143.

    Williams G. C. Nesse R. M. (1991 ). The dawn of Darwinian medicine. Q. Rev. Biol. 66 1–22

    Not in our library10.1086/417048

  144. 144.

    Wilson T. R. Johnston P. G. Longley D. B. (2009 ). Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets 9 307–319

    Not in our library10.2174/156800909788166547

  145. 145.

    Wilson T. R. Longley D. B. Johnston P. G. (2006 ). Chemoresistance in solid tumours. Ann. Oncol. 17(Suppl. 10) x315–x324

    Not in our library10.1093/annonc/mdl280

  146. 146.

    Wong A. L. Lee S. C. (2012 ). Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int. J. Breast Cancer 2012 415170

    Not in our library10.1155/2012/415170

  147. 147.

    Xu Y. Villalona-Calero M. A. (2002 ). Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol. 13 1841–1851

    Not in our library10.1093/annonc/mdf337

  148. 148.

    Yauch R. L. Dijkgraaf G. J. Alicke B. Januario T. Ahn C. P. Holcomb T. (2009 ). Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326 572–574

    Not in our library10.1126/science.1179386

  149. 149.

    Zhang P. Zuo H. Ozaki T. Nakagomi N. Kakudo K. (2006 ). Cancer stem cell hypothesis in thyroid cancer. Pathol. Int. 56 485–489

    Not in our library10.1111/j.1440-1827.2006.01995.x

Cited by papers we hold 16

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.